BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22173648)

  • 1. Current trends in TSH suppression therapy for patients with papillary thyroid carcinoma in Japan: results of a questionnaire distributed to councilors of the Japanese Society of Thyroid Surgery.
    Tanaka K; Sonoo H
    Surg Today; 2012 Jul; 42(7):633-8. PubMed ID: 22173648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.
    Zhang Q; Zhong ZZ; Wu T; He YQ
    BMC Surg; 2024 May; 24(1):133. PubMed ID: 38702652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial.
    Sugitani I; Fujimoto Y
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4576-83. PubMed ID: 20660039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge.
    Nguyen HD; Galitz MS; Mai VQ; Clyde PW; Glister BC; Shakir MK
    Thyroid; 2010 Jan; 20(1):99-103. PubMed ID: 20067380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
    Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
    Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hormonal therapy in differentiated carcinoma of the thyroid gland].
    Francia G; Davì MV; Petroziello A; Sussi PL
    Chir Ital; 1994; 46(4):56-8. PubMed ID: 7882445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The magnitude of increased Levothyroxine dose during pregnancy in patients on thyroid-stimulating hormone (TSH) suppression treatment after total thyroidectomy for papillary carcinoma.
    Minakata M; Ito M; Kishi T; Hada M; Masaki Y; Nakamura T; Kousaka K; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Akamizu T; Miyauchi A
    Endocr J; 2022 Feb; 69(2):165-172. PubMed ID: 34526424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study.
    Sugitani I; Fujimoto Y
    Surgery; 2011 Dec; 150(6):1250-7. PubMed ID: 22136848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical Markers Reflecting Thyroid Function in Athyreotic Patients on Levothyroxine Monotherapy.
    Ito M; Miyauchi A; Hisakado M; Yoshioka W; Ide A; Kudo T; Nishihara E; Kihara M; Ito Y; Kobayashi K; Miya A; Fukata S; Nishikawa M; Nakamura H; Amino N
    Thyroid; 2017 Apr; 27(4):484-490. PubMed ID: 28056660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.
    Cooper DS; Specker B; Ho M; Sperling M; Ladenson PW; Ross DS; Ain KB; Bigos ST; Brierley JD; Haugen BR; Klein I; Robbins J; Sherman SI; Taylor T; Maxon HR
    Thyroid; 1998 Sep; 8(9):737-44. PubMed ID: 9777742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Patients with an Intermediate-Risk Group According to the Japanese Risk Classification of Papillary Thyroid Carcinoma.
    Horiuchi K; Fujimoto M; Hidenori K; Yoshida Y; Noguchi E; Omi Y; Okamoto T
    World J Surg; 2023 Oct; 47(10):2464-2473. PubMed ID: 37266697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
    Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
    Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy.
    Ito M; Miyauchi A; Morita S; Kudo T; Nishihara E; Kihara M; Takamura Y; Ito Y; Kobayashi K; Miya A; Kubota S; Amino N
    Eur J Endocrinol; 2012 Sep; 167(3):373-8. PubMed ID: 22711760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Papillary thyroid carcinoma: justification for total thyroidectomy and management of lymph node metastases.
    Chen H; Udelsman R
    Surg Oncol Clin N Am; 1998 Oct; 7(4):645-63. PubMed ID: 9735127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naming difficulties after thyroid stimulating hormone suppression therapy in patients with differentiated thyroid carcinoma: a prospective cohort study.
    Jin S; Yang YT; Bao W; Bai Y; Ai JW; Liu Y; Yong H
    Endocrine; 2019 Aug; 65(2):327-337. PubMed ID: 31056722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis and prognostic factors of patients with papillary carcinoma showing distant metastasis at surgery (M1 patients) in Japan.
    Ito Y; Masuoka H; Fukushima M; Inoue H; Kihara M; Tomoda C; Higashiyama T; Takamura Y; Kobayashi K; Miya A; Miyauchi A
    Endocr J; 2010; 57(6):523-31. PubMed ID: 20379035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease.
    Fiore E; Vitti P
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1134-45. PubMed ID: 22278420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excellent prognosis of patients with solitary T1N0M0 papillary thyroid carcinoma who underwent thyroidectomy and elective lymph node dissection without radioiodine therapy.
    Ito Y; Masuoka H; Fukushima M; Inoue H; Kihara M; Tomoda C; Higashiyama T; Takamura Y; Kobayashi K; Miya A; Miyauchi A
    World J Surg; 2010 Jun; 34(6):1285-90. PubMed ID: 20041244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
    Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.